FOLD News and Press, Amicus Therapeutics Inc. From 05/26/21

Amicus Therapeutics Inc. (NASDAQ:FOLD) traded today at a new 52-week low of $8.72. Approximately 204,000 shares have changed hands today, as compared to an average 30-day volume of 2.4 million shares. In the past 52 weeks, shares of Amicus Therapeutics Inc. have traded between the curren...

Using the quarterly 13F filings we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion in assets under management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed from and 6 added to the universe now hol...

PHILADELPHIA, May 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 16th International Congress on Neuromuscular Diseases (ICNMD) being held virtually, May ...

Stephen Mandel’s Lone Pine Capital in its recent 13F filing indicated total portfolio value of $27.53B spread across 38 holdings.As per data indicated by Gurfocus.com, Lone Pine's nearly half of equity portfolio is invested in the technology sector followed by smaller holdings in the c...

Image source: The Motley Fool. Amicus Therapeutics Inc (NASDAQ: FOLD) Q1 2021 Earnings Call May 10, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Amicus Therapeutics Inc (FOLD) Q1 2021 Earnings Call Transcript

Amicus Therapeutics, Inc. (FOLD) Q1 2021 Earnings Conference Call May 10, 2021 8:30 a.m. ET Company Participants Andrew Faughnan - Head, IR John Crowley - Chairman and CEO Bradley Campbell - President and COO Daphne Quimi - CFO Jeff Castelli - Chief Development Officer Mitchell Goldman - SVP,...

Amicus Therapeutics (FOLD) reported first-quarter results that missed Wall Street estimates, hurt by the uneven ordering patterns due to the disruptions caused by the COVID-19 pandemic.The company, however, said that it was confident of meeting its FY 2021 financial targets as it ba...

Amicus Therapeutics (FOLD): Q1 GAAP EPS of -$0.25 misses by $0.01.Revenue of $66.4M (+9.7% Y/Y) misses by $5.35M.2021 Financial GuidanceFor the full-year 2021, the Company anticipates total Galafold revenue of $300 million to $315 million. Double-digit revenue growth in 2021 is expected to be...

Galafold ® (migalastat) Performance Reflects Continued Strong Adoption in All Key Global Regions; On-Track to Achieve Revenue Guidance of $300M-$315M 1Q21 Total Galafold Revenue of $66.4M Driven by Continued Global Growth Po...

PHILADELPHIA, May 07, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in May: Bank of America 2021 Health Care Confe...